These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 33006907)

  • 1. Approaches to mitigate the risk of serious adverse reactions in covalent drug design.
    Baillie TA
    Expert Opin Drug Discov; 2021 Mar; 16(3):275-287. PubMed ID: 33006907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electrophilic warheads in covalent drug discovery: an overview.
    Péczka N; Orgován Z; Ábrányi-Balogh P; Keserű GM
    Expert Opin Drug Discov; 2022 Apr; 17(4):413-422. PubMed ID: 35129005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expanding repertoire of covalent warheads for drug discovery.
    Mehta NV; Degani MS
    Drug Discov Today; 2023 Dec; 28(12):103799. PubMed ID: 37839776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug discovery for a new generation of covalent drugs.
    Kalgutkar AS; Dalvie DK
    Expert Opin Drug Discov; 2012 Jul; 7(7):561-81. PubMed ID: 22607458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies.
    Bauer RA
    Drug Discov Today; 2015 Sep; 20(9):1061-73. PubMed ID: 26002380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The resurgence of covalent drugs.
    Singh J; Petter RC; Baillie TA; Whitty A
    Nat Rev Drug Discov; 2011 Apr; 10(4):307-17. PubMed ID: 21455239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
    Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
    Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Covalent Inhibitors for Drug Design.
    Baillie TA
    Angew Chem Int Ed Engl; 2016 Oct; 55(43):13408-13421. PubMed ID: 27539547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arylfluorosulfate-Based Electrophiles for Covalent Protein Labeling: A New Addition to the Arsenal.
    Martín-Gago P; Olsen CA
    Angew Chem Int Ed Engl; 2019 Jan; 58(4):957-966. PubMed ID: 30024079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Label-Free Bottom-Up Proteomic Workflow for Simultaneously Assessing the Target Specificity of Covalent Drug Candidates and Their Off-Target Reactivity to Selected Proteins.
    Yang Y; Shu YZ; Humphreys WG
    Chem Res Toxicol; 2016 Jan; 29(1):109-16. PubMed ID: 26675335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug metabolism and metabolite safety assessment in drug discovery and development.
    He C; Wan H
    Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):1071-1085. PubMed ID: 30215280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on the discovery and development of reversible covalent inhibitors.
    Faridoon ; Ng R; Zhang G; Li JJ
    Med Chem Res; 2023; 32(6):1039-1062. PubMed ID: 37305209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using quantitative systems pharmacology for novel drug discovery.
    Pérez-Nueno VI
    Expert Opin Drug Discov; 2015 Dec; 10(12):1315-31. PubMed ID: 26328768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benchmarking in vitro covalent binding burden as a tool to assess potential toxicity caused by nonspecific covalent binding of covalent drugs.
    Dahal UP; Obach RS; Gilbert AM
    Chem Res Toxicol; 2013 Nov; 26(11):1739-45. PubMed ID: 24164572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced approaches of developing targeted covalent drugs.
    Gai C; Harnor SJ; Zhang S; Cano C; Zhuang C; Zhao Q
    RSC Med Chem; 2022 Dec; 13(12):1460-1475. PubMed ID: 36561076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation.
    Zhang T; Hatcher JM; Teng M; Gray NS; Kostic M
    Cell Chem Biol; 2019 Nov; 26(11):1486-1500. PubMed ID: 31631011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Covalent drug discovery using sulfur(VI) fluoride exchange warheads.
    Huang H; Jones LH
    Expert Opin Drug Discov; 2023 Jul; 18(7):725-735. PubMed ID: 37243622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detecting reactive drug metabolites for reducing the potential for drug toxicity.
    Grillo MP
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1281-302. PubMed ID: 26005795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Lead compound optimization strategy (2)--structure optimization strategy for reducing toxicity risks in drug design].
    Liu HL; Wang J; Lin DZ; Liu H
    Yao Xue Xue Bao; 2014 Jan; 49(1):1-15. PubMed ID: 24783499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. bioTCIs: Middle-to-Macro Biomolecular Targeted Covalent Inhibitors Possessing Both Semi-Permanent Drug Action and Stringent Target Specificity as Potential Antibody Replacements.
    Yang J; Tabuchi Y; Katsuki R; Taki M
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.